Neola Medical AB
The answer first
Does Neola Medical beat the market?
No, Neola Medical has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 36% of Nordic stocks
- Quality86
- Value25
- Trend23
No. 90 of 195 in healthcare
Max for seven days
Follow Neola Medical with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 20 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Neola Medical
Your first answer is free, no account needed.
Do you own Neola Medical, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Neola Medical and a few more. Free, no card.
Super Stock+45.4%In short
- Neola Medical has fallen 64.2% over the past year, including dividends.
- Overall, Neola Medical ranks better than 36% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 85.8%. The price is 91.9% below its peak now.
What do analysts think of Neola Medical?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 36% of Nordic stocks.
No. 90 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 41 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity–
- Asset turnoverSales divided by everything the company owns0.00
- Return on equityProfit divided by equity−13.0%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 82 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity0.4
- P/SPrice divided by sales–
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 121 of 198 in healthcareTypical in healthcare: 33Typical in the Nordics: 50
- 3 months+2.2%
- 6 months−52.0%
- 9 months−42.4%
- 12 months−64.2%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Neola Medical
2 funds we follow own Neola Medical. The share is how much of the fund the stock makes up.
- Sweden2
From the funds' latest known holdings.
About Neola Medical
Neola Medical AB is a company in healthcare, listed on Nasdaq Stockholm. By market value, Neola Medical is number 112 of 137 companies in healthcare on Nasdaq Stockholm. Neola Medical has not paid a dividend in the past twelve months. Of the three measures in the ranking, Neola Medical is strongest on quality, better than 86% of Nordic stocks. The share trades in SEK. It has around 9 employees.
Neola Medical AB (publ), together with its subsidiary, Neola Medical, Inc., develops medical technology devices for non-invasive continuous monitoring of the lungs of preterm born infants in Sweden. It offers NEOLA, a neonatal intensive care medical device that enables continuous lung monitoring and real-time alerts of life-threatening complications using technology that measures lung volume changes and oxygen gas concentration. The company was formerly known as GPX Medical AB and changed its name to Neola Medical AB (publ) in June 2022. Neola Medical AB (publ) was incorporated in 2016 and is headquartered in Lund, Sweden.


See the full analysis of Neola Medical.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card